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A key aspect for the clinical handling of acute kidney injury is
an early diagnosis, for which a new generation of urine
biomarkers is currently under development including kidney
injury molecule 1 and neutrophil gelatinase-associated
lipocalin. A further diagnostic refinement is needed where
one specific cause among several potentially nephrotoxic
insults can be identified during the administration of
multidrug therapies. In this study we identified increases in
regenerating islet-derived protein III beta (reg IIIb) and
gelsolin as potential differential urinary markers of
gentamicin’s nephrotoxicity. Indeed, urinary levels of both
reg IIIb and gelsolin distinguish between the nephrotoxicity
caused by gentamicin from that caused by cisplatin where
these markers were not increased by the latter. Reg IIIb was
found to be overexpressed in the kidneys of gentamicin-
treated rats and excreted into the urine, whereas urinary
gelsolin originated from the blood by glomerular filtration.
Our results illustrate an etiological diagnosis of acute kidney
injury through analysis of urine. Thus, our results raise the
possibility of identifying the actual nephrotoxin in critically ill
patients who are often treated with several nephrotoxic
agents at the same time, thereby providing the potential for
tailoring therapy to an individual patient, which is the aim of
personalized medicine.
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Gentamicin is an aminoglycoside antibiotic widely used
worldwide against Gram-negative infections. Its therapeutic
efficacy and use are severely handicapped by its toxicity,
which mainly occurs at the renal and auditory levels.1
Gentamicin-induced nephrotoxicity appears in 10–25% of
therapeutic courses.2–4 It is characterized mostly by tubular
damage,5,6 but glomerular1,7–11 and vascular12–14 alterations
might also appear in a dose-dependent manner.15 Tubular
damage affects mainly the proximal compartment,5 and it
results in a reduced glomerular filtration rate through (1) an
impairment of the reabsorption capacity that activates the
tubuloglomerular feedback to prevent massive fluid loss;16
and (2) an increased intratubular pressure resulting from
tubular obstruction by tissue debris.5 In the glomeruli,
gentamicin produces contraction of mesangial cells, which
diminishes the ultrafiltration coefficient (Kf).
1,8,17,18 As a
polycation, gentamicin also alters the electrical properties of
the glomerular filtration barrier (GFB).19,20 Finally, gentami-
cin reduces renal blood flow (RBF) by contracting both
preglomerular arteries and the afferent and efferent arter-
ioles.12 As a consequence of a diminished RBF, glomerular
filtration rate becomes deteriorated. A lower RBF also
contributes to tissue necrosis, especially within the cortical
area.21 Glomerular and vascular contraction is mediated by
locally increased autacoids like arachidonic acid derivatives
(that is, thromboxane A2; Papanikolaou et al.22), platelet-
activating factor,6,23 and endothelin-1.24–26 Vasoconstriction
might also be related to deterioration of the relaxing capacity
of the vascular smooth muscle.14
Depending on other comorbid conditions, gentamicin-
associated nephrotoxicity may lead to an acute renal failure
(ARF), an extremely serious condition resulting from an
abrupt loss of the kidneys’ excretory function sufficient to
prevent blood cleansing of waste products, and to impair
water and electrolytic balance.27–29 ARF poses an enormous
human and socioeconomic burden derived from its high
incidence and mortality rate. It is estimated that nearly 1% of
hospital admissions are associated with ARF, and B2–7% of
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hospitalized patients eventually develop ARF.30,31 Most
importantly, mortality among ARF patients stays strikingly
high at B50% of the cases in spite of dialysis instaura-
tion.30–32 This rate grows up to an 80% when ARF courses
with multiorgan damage.30,32,33 The most effective handling
of ARF relies on the earliest possible detection, upon which
hydration and treatment withdrawal or regime modifications
are applied. Other occasional measurements include the pre-
emptive administration of renoprotective drugs, such as the
antioxidants N-acetylcysteine34–37 or amifostine,38 and other
molecules presently under development for the prevention of
renal injury. Intervention on severe cases relies mostly on
dialysis.
In the clinical practice, ARF is diagnosed when renal
dysfunction induces an increase in creatinine and urea levels
in the blood. However, at this stage, glomerular filtration rate
is already decreased and ARF becomes difficult to handle. As
such, present diagnostic tendencies aim at detecting incipient
pathophysiological events occurring at early stages, when
damage is less extensive.32,39–41 Measurement of urinary
enzymes originating from renal tissue injury, including
N-acetyl-b-D-glucosaminidase (NAG) and others,40 is pre-
sently the finest method for an early detection of ARF
coursing with tubular damage. New, early urine markers are
currently in an advanced degree of validation for the
diagnosis and prognosis of ARF, including kidney injury
molecule 1 (KIM-1), neutrophil gelatinase-associated lipoca-
lin (NGAL), and others.40,42
The next step in the refinement of ARF diagnosis will be
the capability to differentiate the renal damage inflicted by a
determined drug or insult from that exerted by others.43 It
could be based on specific collections of markers composing
a molecular fingerprint for every potential nephrotoxicant.
This new diagnostic capability will be very useful for a more
rational, individualized, and specific handling of clinical
situations coursing with symptoms of renal damage, as for
example, in the case of polymedicated patients receiving
cotreatments containing two or more drugs being potentially
nephrotoxic. This will allow us to correctly redirect the
treatment by substituting only the harmful drug or by
reshaping its therapeutic regime. In this article, we identify
regenerating islet-derived protein III b (reg IIIb) and
gelsolin as new urinary markers to further profile and
differentiate the AKI inflicted by gentamicin from that
induced by cisplatin.
RESULTS
Characterization of the renal lesion induced by gentamicin
As expected, after 6 days of treatment, gentamicin caused
a marked ARF with an associated mortality of B50%
(Figure 1b). Surviving animals coursed with a small but
significant weight loss and polyuria. ARF was further
characterized by a dramatic increase in plasma creatinine
and urea concentration, suggesting a reduction of glomerular
filtration rate (Figure 1a). NAG (Figure 1a), KIM-1, and bone
morphogenetic protein 7 (Figure 1c) urinary excretion also
increased, indicating tubular damage. Proteinuria was also
evident in the urine of animals treated with gentamicin
(Figure 1a). Hematoxylin–eosin-stained renal sections
(Figure 1d) revealed a clear tubular necrosis in gentamicin-
treated rats. No gross modification of the glomeruli was
evident. At the papillary level, obstruction of collecting tubuli
with hyaline material was widespread in gentamicin-treated
animals.
Differential proteomic analysis of the urine
A representative image of two-dimensional (2D) gels (pH
range 4–7) of urine samples from control and gentamicin-
treated rats is shown in the upper panels of Figure 2.
Many proteins concentrate in the range of pH 4.5–5.5. For that
reason, 2D separations in this pH range were also done with
the same urine samples. A representative image of the latter is
shown in the lower panels of Figure 2. A great similarity was
observed between samples from animals in the same group,
and high reproducibility was obtained when repeating the 2D
separation with the same sample, for quality assurance.
However, the urine proteome of both groups is substantially
different. Statistically significant, differentially present spots
between control and gentamicin groups were recognized and
numbered for chemical identification. Mass spectrometric
analysis revealed the identity of two proteins increased in the
urine of gentamicin-treated rats, which showed potential
interest after discarding most of the other proteins, normally
found in different proteinuric conditions. They were identified
as reg IIIb and gelsolin (Figure 2).
Reg IIIb and gelsolin are differentially excreted in the urine
of rats treated with gentamicin
The increased urinary level of these proteins in the urine of
gentamicin-treated rats was confirmed by western blot
analysis. Moreover, the urine from rats treated with a
nephrotoxic regime of cisplatin was also analyzed.
Figure 3b shows data on plasma creatinine concentration
and blood urea nitrogen from 6 control rats, 6 rats treated
with gentamicin, and 6 rats treated with cisplatin. It
demonstrates that animals treated with gentamicin or
cisplatin developed an overt renal failure as demonstrated
by the increment in plasma blood urea nitrogen and
creatinine, increased NAG excretion, and the decrease
in creatinine clearance. These urine samples were also
analyzed for their content in reg IIIb and gelsolin.
Figure 3a clearly shows that the urinary level of reg IIIb
is markedly increased only in gentamicin-treated animals,
despite undergoing a similar degree of renal damage than
cisplatin-treated rats. Western blot of gelsolin revealed two
reactive bands. The higher one corresponds to the full-
length protein, whereas the lower one corresponds to a
fragment thereof. The presence of gelsolin within the reactive
bands was further re-confirmed by tandem mass spectra.
Treatment with gentamicin induces the appearance in the
urine of both the full-length gelsolin and the B43 kDa
fragment. However, the full-length band was absent in the
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Figure 1 |Characterization of the renal damage induced by gentamicin. (a) Body weight (shown as a percentage of the initial weight), plasma
creatinine concentration, creatinine clearance (ClCr), plasma urea concentration, proteinuria, N-acetyl-b-D-glucosaminidase (NAG) excretion, and
urine flow parameters of rats from control and gentamicin groups after 6 days of treatment. (b) Survival rate represented as a percentage of
surviving animals in each group after 6 days of treatment. (c) Representative images of western blot analysis of kidney injury molecule 1 (KIM-1)
and bone morphogenetic protein 7 (BMP-7) expression levels in kidney homogenates from 3 randomly selected, control, and 3 gentamicin rats
after 6 days of treatment. (d) Representative images (original  1000 magnification) of renal sections stained with hematoxylin and eosin from
gentamicin and control rats. Data represent the average±s.e.m. AU, arbitrary units; B, basal time point; aPp0.05 with respect to the control
group. In both groups, n¼ 12 at the beginning of the experiment.
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urine of all rats treated with cisplatin, except for one of them.
Extensive analysis of the urine from other cisplatin-treated
rats shows no presence of the full-length band (data not
shown).
Time course evolution of reg IIIb and gelsolin urinary
excretion in rats treated with gentamicin or cisplatin
We further analyzed the time course evolution of the urinary
excretion of these proteins in rats treated with gentamicin or
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Figure 2 |Urinary proteomics. Two-dimensional (2D) gel images of differentially expressed regenerating islet-derived protein III b (reg IIIb) and
gelsolin. Spots were subject to quantitative intensity analysis, labeled with numbers corresponding to those in table, and identified by liquid
chromatography-electrospray ionization-quadrupole time-of-flight (LC-ESI-Q-TOF) mass spectrometry. Each gel shown in this figure is
representative of eight gels obtained with urine from four randomly selected animals in each group, each one analyzed in duplicate.
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cisplatin. Figure 4 shows the temporal profile of the renal
damage inflicted by gentamicin. Significant damage only
occurs after 4 days of treatment, as revealed by the evolution
of plasma creatinine, NAG excretion, proteinuria, and the
urinary level of three sensitive markers of kidney injury, such
as KIM-1, NGAL, and PAI-1 (plasminogen activator
inhibitor 1). Congruently with the accumulated knowledge,44
plasma creatinine is the least sensitive of all the markers
tested. Furthermore, histological analysis of renal sections
after 3 days of treatment reveals no findings of tubular
damage. At this time point, cytoplasmic vacuolation of
tubule epithelial cells is evident (Figure 4d), probably
resulting from the reported accumulation of gentamicin in
the endosomal compartment,45,46 and from alteration of the
endocytic pathway and the endosomal trafficking.47,48 In this
scenario, western blot analysis showed that reg IIIb appears in
the urine along with most other sensitive markers of renal
injury, starting on day 4. Interestingly, urinary gelsolin (the
B43 kDa fragment) appears as early as on day 1 and stays
high through the treatment, long before all other sensitive
markers do, including KIM-1, PAI-1, NGAL, and NAG. In
the case of rats treated with cisplatin, reg IIIb and full-length
gelsolin are not significantly increased in the urine during the
same period of 6 days (Figure 5a), despite that rats treated
with cisplatin develop a similar degree of renal injury to that
observed in gentamicin-treated rats. This is evidenced by the
evolution of parameters of renal dysfunction and damage,
such as plasma creatinine, urinary excretion of NAG and
KIM-1, and by the histological examination of renal tissue
after 6 days of treatment with both drugs (Figure 5a–c, and
also Figures 3 and 4). Yet, the level of the 43 kDa fragment of
gelsolin increases in the urine of rats treated with cisplatin
more pronouncedly than and before KIM-1 (Figure 5a),
which also occurs in the case of the treatment with
gentamicin (Figure 4). This can be potentially exploited for
an early diagnosis of AKI.
Origin of urinary reg IIIb and gelsolin
Western blot analysis of albumin-depleted plasma from
control and gentamicin-treated rats indicated that reg IIIb is
absent (to the detection limit of this technique), whereas
gelsolin is normally found in the blood compartment. Even
more, gentamicin treatment slightly increases the plasmatic
level of the latter (Figure 6a). Gene expression analysis
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Figure 3 |Validation of the increased urinary excretion of regenerating islet-derived protein III b (reg IIIb) and gelsolin. (a) Western
blot analysis of reg IIIb and gelsolin in the urine of six randomly selected rats treated with vehicle (control), gentamicin, or cisplatin. Arrows
indicate the full-length and t-gelsolin fragment. (b) Densitometric quantification of the reg IIIb and full-length gelsolin bands from a.
(c) Plasma creatinine and urea concentration of rats as in a. Data represent the average±s.e.m. AU, arbitrary units; *Po0.05 vs control;
KPo0.05 vs gentamicin.
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carried out on renal tissue by reverse transcriptase-PCR
showed that these two proteins are normally expressed
in the kidneys. Treatment of rats with gentamicin does
not modify the renal expression pattern of gelsolin, but
induces an increase in reg IIIb gene expression as early as on
day 3 (Figure 6b), when no detectable kidney injury has
occurred yet (Figure 4). On day 6, reg IIIb expression is
highest.
In order to study whether the origin of these urinary
proteins was the blood, which would shed them to the urine
through the GFB, we perfused the kidneys of rats treated for 6
days with gentamicin with Krebs solution (containing
dextran to compensate for the oncotic pressure). We found
that immediately before substituting the renal blood flow
with Krebs, we could still detect reg IIIb and gelsolin in the
urine (Figure 6c). However, once the renal blood flow was
substituted with Krebs flow, gelsolin disappeared from the
urine; yet, the upper band of reg IIIb was still detected,
whereas the lower one disappeared.
DISCUSSION
Nephrotoxicity poses a considerable health and economic
problem worldwide. It is an important reason of failure along
the drug discovery process, which leads to discarding
otherwise clinically interesting molecules.49,50 Most impor-
tantly, B25% of the 100 most used drugs in intensive care
units are potentially nephrotoxic.51 Overall, it is estimated
that nephrotoxicity is responsible for 10–20% of the acute
renal failure cases.52 A critical aspect for the optimal clinical
handling of AKI is an early diagnosis.53,54 Important progress
has been made in the last decade toward an increasingly
earlier detection based on novel and more sensitive urinary
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Figure 4 | Time course evolution of urinary regenerating islet-derived protein III b (reg IIIb) and gelsolin in rats treated with
gentamicin. (a) Representative images of western blot analysis of urinary reg IIIb and gelsolin; densitometric quantification of the reg IIIb
and t-gelsolin bands from three western blots carried out with the urine of three unselected rats; and western blot analysis of kidney injury
molecule 1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and plasminogen activator inhibitor 1 (PAI-1) evolution. (b) Plasma
creatinine concentration. (c) Evolution of N-acetyl-b-D-glucosaminidase (NAG) excretion and proteinuria of rats treated with gentamicin.
(d) Representative image of renal sections stained with hematoxylin and eosin from rats treated with gentamicin for 3 days (original
magnification  1000). In all experiments, n¼ 3. Data represent the average±s.e.m. AU, arbitrary units; *Po0.05 vs time 0.
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markers.40 However, AKI diagnosis may still be improved in
an individual-drug basis, for enhanced theranostics and a
more individualized medicine. In this article we provide
some evidence on new urinary markers with a potential to
differentiate the nephrotoxicity of gentamicin from that
caused by cisplatin, and to detect the renal effects of
gentamicin earlier with state-of-the-art AKI markers. They
will help to better delineate the pharmacological profile of
gentamicin and, in turn, to improve its clinical utility.
Both reg IIIb and full-length gelsolin have potential for a
differential or etiological diagnosis of gentamicin’s nephro-
toxicity. They appear in the urine of rats with overt renal
failure induced by gentamicin, but are not present in the
urine of rats with a similar degree of renal damage inflicted
by cisplatin. Reg IIIb is a 17 kDa member of the calcium-
dependent lectin (C-type lectin) superfamily55 comprising
several secretory protein products of four genes (Reg I, II, III,
and IV). Reg genes have been found in different mammal
species including human, rat, and mouse. Rat Reg genes map
to the 4q33–q34 chromosomal region.56 In humans, all Reg
genes, except Reg IV, map to the 2p12 region.57 In general
terms, Reg family proteins are involved in tissue regeneration
in a number of physiological and pathological situations,
most prominently including pancreatitis, and also hepatic
injury, diabetes, and cancer.55 Our experiments suggest that
reg IIIb may be implicated in renal tissue injury and repair
during gentamicin treatment and, importantly, that it might
be used as a differential urinary marker. Because we could not
detect this protein in the blood, we thought that urinary reg
IIIb may be originated in the renal tissue. Indeed, our data
indicate that reg IIIb expression is strongly induced by
gentamicin in the kidneys, even preceding urine and
plasmatic markers and histological findings of nephrotoxicity
(on day 3 of treatment; Figure 5b). The renal origin of reg
IIIb upon treatment with gentamicin is further supported by
our experiments on renal perfusion. When we acutely
substituted the RBF for perfused Krebs solution in rats
previously treated with gentamicin, we still observed reg IIIb
in the urine (Figure 5c). Urinary reg IIIb appears as a double
band in western blot analysis, corresponding to a double spot
in 2D gels. However, when blood is substituted for Krebs in
the renal circuit of gentamicin-treated rats, only the upper
band is detected in the urine. We can only speculate that the
lower band corresponds to a proteolytic fragment produced
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Figure 5 | Time course evolution of urinary regenerating islet-derived protein III b (reg IIIb) and gelsolin in rats treated with
cisplatin. (a) Representative images of western blot analysis of urinary reg IIIb, gelsolin (full-length and the t fragment, indicated by the
arrows), and kidney injury molecule 1 (KIM-1), and densitometric quantification of three independent experiments. (b) Evolution of plasma
creatinine concentration and N-acetyl-b-D-glucosaminidase (NAG) excretion; n¼ 6. (c) Representative images of the cortex and medulla in
renal sections stained with hematoxylin and eosin from rats treated with cisplatin (day 6 after cisplatin injection; original magnification
 1000; n¼ 3). Data represent the average±s.e.m. *Po0.05 vs time 0; AU, arbitrary units; Cþ , positive control (that is, urine from a
gentamicin-treated, nephrotoxic rat).
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by serum proteases, or renal proteases activated by serum
components.
Gelsolin is a highly conserved 82 kDa protein involved in
cytoskeleton organization and rearrangement in a number
of normal cellular processes including motility, signaling,
and apoptosis,58 and pathophysiological conditions such as
inflammation, cancer, and amyloidosis.59,60 Gelsolin is
expressed in many cell types and is also secreted and found
normally in the blood of vertebrates.60,61 Gelsolin is a known
substrate for effector caspase 3, which yields a 42 kDa
proteolytic fragment (t-gelsolin62) involved in the execu-
tion63 and regulation58,62,64 of apoptosis. Our results indicate
that urinary gelsolin may also be developed as a marker for
the differential diagnosis of gentamicin’s nephrotoxicity. In
fact, the band corresponding to the full-length protein in
western blot studies appears in the urine of gentamicin-
treated rats, but it is mostly absent in cisplatin-treated rats.
On the contrary, the B43 kDa band in our gels, likely
t-gelsolin, is common to both gentamicin and cisplatin groups.
The results shown in Figure 5 indicate that gelsolin gene
expression is not modified in the kidneys of rats treated with
gentamicin (with respect to controls). They further show that
gelsolin disappears from the urine when RBF is substituted for
Krebs, suggesting that urinary gelsolin is probably filtered from
the blood through the GFB. This may also explain why the
full-length gelsolin is detected in the urine of rats treated with
gentamicin and not in those treated with cisplatin, whereas
t-gelsolin appears after both treatments. Gentamicin alters the
GFB properties, leading to an increase in filtration of specific
proteins.19,20 The polycationic charge of gentamicin alters the
electrostatic properties of the GFB, increasing the permeability
of negatively charged proteins (such as gelsolin, pI¼ 5.75) and
lowering the sieving coefficient of positively charged ones.65
No alterations of the GFB sieving properties have been
reported for cisplatin. In this case, full-length gelsolin would be
excluded from passing through the GFB for size restric-
tion.66,67 However, t-gelsolin would not be trapped in the
blood in any case because its lower size allows it to filter more
easily through the GFB. In a scenario of tubular necrosis, a
larger amount of proteins escapes the handicapped tubular
reabsorption capacity, which can be detected in the urine. As
shown in Figure 4, t-gelsolin appears in the urine of
gentamicin-treated rats significantly earlier than traditional
and new AKI markers, the latter including KIM-1, NGAL,
NAG, and PAI-1. This might also be exploited for an early
monitoring of gentamicin’s nephrotoxicity.
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Figure 6 |Origin of urinary regenerating islet-derived protein III b (reg IIIb) and gelsolin. (a) Representative images of western blot analysis
of the plasma level of reg IIIb and gelsolin from two randomly selected rats treated with vehicle (control) or gentamicin for 6 days. (b) Renal
tissue reg IIIb, gelsolin, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene expression by reverse transcriptase-PCR (RT-PCR)
from three randomly selected rats treated with vehicle (control) or gentamicin for 3 and 6 days; and densitometric quantification of RT-PCR
bands. AU, arbitrary units. (c) Renal perfusion experiments. Representative mages of western blot analysis of the urinary level of reg IIIb and
gelsolin from rats treated with gentamicin for 6 days, and then subject to renal perfusion with Krebs solution, immediately before the
beginning of perfusion (B) and 1 and 2 h during perfusion; n¼ 3. Data represent the average±s.e.m. *Po0.05 vs control; KPo0.05 vs day 3.
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The present study provides two novel urinary biomarker
candidates for the differential diagnosis of gentamicin’s
nephrotoxicity, which need to be further developed in the
preclinical and clinical settings for a better theranostic usage
and efficacy of this drug. This includes the technological
development of more practical detection methods for clinical
use. Moreover, it poses a proof of principle for the potential
application of the etiological diagnosis of AKI to critical
patients coursing with multiple conditions potentially
affecting renal integrity, including polymedication. Etiologi-
cal diagnosis should be extended to many other potentially
nephrotoxic drugs widely used in the clinical practice, and on
pre-and post-renal causes of AKI. This will enable us to
delineate patterns of markers that specifically discriminate
the origin of undesirable renal effects in order to appro-
priately and selectively reshape the clinical handling and
therapeutic regimes of patients at risk.
MATERIALS AND METHODS
Unless otherwise indicated, all reagents were purchased from Sigma
(Madrid, Spain). Gentamicin sulfate was kindly provided by
Schering-Plough (Madrid, Spain).
Animals and experimental protocol
Animals were treated in accordance with the Declaration of Helsinki
Principles and the Guiding Principles in the Care and Use of
Animals stated in the international regulations and in the following
European and national institutions: Conseil de l’Europe (published
in the Official Daily N. L358/1-358/6, 18 December 1986), Spanish
Government (published in Boletı´n Oficial del Estado N. 67, pp
8509-8512, 18 March 1988, and Boletı´n Oficial del Estado N. 256,
pp 31349-31362, 28 October 1990). Female Wistar rats weighing
200–250 g were allocated under controlled environmental conditions
in individual metabolic cages, for 24-h urine samples collection.
Rats were randomly divided into three groups: (1) control group
(C), receiving daily vehicle intraperitoneal for 6 days; (2) gentamicin
group (G), receiving gentamicin intraperitoneal (150mg/kg body
weight per day) for 6 days; and (3) cisplatin group (Cisp), receiving
one intraperitoneal dose of cisplatin (7.5mg/kg). At the end of the
experiment in all cases, and at day 3 in some gentamicin-treated
rats, kidneys were perfused by the aorta with saline (0.9% NaCl) and
immediately dissected. One was frozen in liquid nitrogen and
subsequently kept at 80 1C for western blot studies. The other one
was fixed in buffered 3.7% p-formaldehyde for histological studies.
Blood samples were also obtained in heparinized capillaries at
different time points by a small incision in the tail tip. Blood was
centrifuged and plasma was kept at 80 1C until use. Urine was
cleared by centrifugation, and it was stored at 80 1C until use.
Histological studies
Paraffin blocks were made and 5-mm tissue sections were stained
with hematoxylin and eosin. Photographs were taken using an
Olympus BX51 microscope connected to an Olympus DP70 color,
digital camera (Olympus, Barcelona, Spain).
Biochemical measurements
Plasma and urinary creatinine (Crp and Cru, respectively) and blood
urea concentration were measured using automated analyzer
Reflotron (Roche Diagnostics, Barcelona, Spain; lower detection
limit of 0.5mg/dl). Creatinine clearance (ClCr)¼Cru 24-h urine
outputCrp1. Urine protein concentration was measured using the
Bradford method.68 Urine NAG content was determined by a
colorimetric method with a commercial kit (Roche Diagnostics)
based on the conversion of 3-cresolsulfonphthaleinyl-N-acetyl-b-
D-glucosaminide into the purple 3-cresol-cresolsulfonphthaleinyl.
Western blot
Western blots were run with (1) urine samples (21ml per sample), (2)
tissue extracts (100mg total protein per sample) prepared by
homogenizing the kidneys with a tissue mixer (Ultra-Turrax T8,
IKA-Werwe; IKA, Staufen, Germany) at 4 1C in homogenization
buffer (140mmol/l NaCl, 20mmol/l Tris-HCl pH¼ 7.5, 0.5M EDTA,
10% glycerol, 1% Igepal CA-630, 1 mg/ml aprotinin, 1mg/ml
leupeptin, 1mg/ml pepstatin A, and 1mmol/l phenylmethylsulphonyl
fluoride), or (3) albumin-free blood plasma. Albumin was removed
from plasma with a column-based, commercial kit based on the
immunological retention of rat albumin (Qproteome Murine
Albumin Depletion Kit; Quiagen, Madrid, Spain). Samples were
separated by electrophoresis in 10–15% acrylamide gels (Mini
Protean II system; Bio-Rad, Madrid, Spain). Immediately, proteins
were electrically transferred to an Immobilon-P membrane (Milli-
pore, Madrid, Spain). Membranes were probed with antibodies
against KIM-1 (R&D Systems, Minneapolis, MN), bone morphoge-
netic protein 7 (Santa Cruz Biotechnology, Santa Cruz, CA), NGAL
(MBL, Woburn, MA), PAI-1 (BD Biosciences, Madrid, Spain), reg
IIIb (R&D Systems), and gelsolin (Santa Cruz Biotechnology). The
signal obtained was quantified by densitometry using the Scion
Image software (Scion Corporation, Frederick, MD).
Two-dimensional electrophoretic separation of proteins
Urine was concentrated and desalted through Amicon Ultra 5K
cutoff columns (Millipore). Protein concentration was determined
using the Bradford method. For 2D electrophoresis, urine proteins
(100 mg) were precipitated with the Clean-Up kit (GE Healthcare,
Madrid, Spain). Precipitated proteins were rehydrated in 7 M urea,
2 M thiourea, 4% (w/v) Chaps, 0.5% ampholytes (pH 4–7 or 4.5–5.5),
50mmol/l dithiothreitol, and bromophenol blue, and isoelectrically
focused (500–8000V) through 18-cm long IPG (immobilized pH
gradient) strips, pH 4–7 or 4.5–5.5 (GE Healthcare), using an
IPGphor apparatus (GE Healthcare). After focusing, IPG strips were
pre-equilibrated for 15min in equilibration buffer (50mmol/l
Tis-HCl pH¼ 8.8, 6 M urea, 30% (v/v) glycerol, 2% (w/v) sodium
dodecyl sulfate, 0.01% (w/v) bromophenol blue) containing 1%
(w/v) dithiothreitol, and for another 15min in equilibration buffer
containing 2.5% (w/v) iodoacetamide. IPG strips were then
transferred to 18-cm long, 12% acrylamide gels and separated by
electrophoresis with the SE 600 Ruby apparatus (GE Healthcare).
Gels were fixed overnight in 30% ethanol, 10% acetic acid, and silver
stained with a commercial kit (GE Healthcare).
For visualization and analysis, gels were scanned (Image Scanner;
GE Healthcare), processed, and statistically analyzed with the Image
Master 2D Platinum 6.0 software (GE Healthcare). Spot discrimina-
tion was done with the following parameters: (1) smooth factor: 2;
(2) minimal area: 5 pixels; and (3) saliency: 100. Analysis was
visually corrected for artifact elimination. For each individual spot,
background was subtracted and individual intensity volume was
normalized by total intensity volume (all-spot intensity). For
comparison of the same spot among gels, a minimum of a twofold
intensity difference (with Po0.01 according to Student’s t-test) was
established to consider a differential expression.
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Protein identification by mass spectrometry
The spots of interest from 2D separations were cut off the gels,
dehydrated in acetonitrile, vacuum evaporated, and resuspended in
NH4HCO3. The two-dimensional liquid chromatography fractions
were also vacuum evaporated and residues re-suspended in
NH4HCO3. Samples were then reduced with 10mmol/l dithiothrei-
tol in 50mmol/l NH4HCO3 at 56 1C, and alkylated with iodo-
acetamide in 50mmol/l NH4HCO3. Proteins were in-gel digested
with porcine trypsin (Promega, Madrid, Spain), and peptides were
extracted with 0.5% (v/v) trifluoroacetic acid, vacuum evaporated,
and redissolved in 0.1% (v/v) formic acid. Peptide-containing
solutions were injected in a LC-ESI-QUAD-TOF (liquid chromato-
graphy-electrospray ionization-quadrupole time-of-flight) mass
spectrophotometer QSTAR XL (Applied Biosystems, Carlsbad,
CA) with an 1100 micro HPLC (Agilent, Madrid, Spain). A wide
pore 150 0.32mm (5mm) Supelco column (Discovery BIO,
Seattle, WA) was used. Tandem mass spectra were obtained. Protein
identification was performed using the MASCOT software
(www.matrixscience.com) against non-redundant protein sequence
databases (Swiss Prot and National Center for Biotechnology
Information). Mass tolerance was set at 50 p.p.m., tandem mass
spectra tolerance was 0.5Da, and the taxonomic status was Rattus.
Only significant hits, as identified by MASCOT probability analysis,
were considered and at least one peptide match with ion score above
20 was set as the threshold of acceptance. For confirmation,
some proteins were also identified with an Ultraflex I MALDI-TOF
(matrix-assisted laser desorption/ionization time-of-flight) mass
spectrophotometer (Bruker Daltonics, Bremen, Germany).
Gene expression analysis
Reverse transcriptase-PCR amplification of reg IIIb, gelsolin, and
GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was per-
formed with the following primers: for rat reg IIIb, 50-TTGTTTGAT
GCAGAACTGGC-30 and 50-AGACGTAGGGCAACTTCACT-3; for
rat gelsolin, 50-CAAGGCTACTTCAAGTCTGG-30 and 50-GCTACC
CTCTTCAGACACAT-3; for rat GAPDH, 50-GTGGTCATGAGCC
CTTCCA-30 and 50-AACTCCCTCAAGATTGTCAGCAA-30. PCR
conditions were: 1 (95 1C 4min); 30 (95 1C 1minþ
Tm 1min); and 1 (72 1C 10min); where Tm was 55.5 1C for
reg IIIb, 55.0 1C for gelsolin, and 55.9 1C for GAPDH. The signal
obtained was quantified by densitometry using the Scion Image
software.
Excretion studies with in situ perfused kidneys
At the end of the treatment, rats treated with gentamicin for 6 days
were anesthetized and an extracorporeal circuit for kidney perfusion
was set up, as described elsewhere,69 with some modifications.
Briefly, the renal artery, vein, and ureter of the right kidney were
ligated. The renal artery and vein of the left kidney and the urinary
bladder were cannulated. Oxygenated and warm (37 1C) Krebs-
dextran (40 g/l of dextran (molecular weight 64K–76K) in Krebs
solution (118.3mmol/l NaCl, 4.7mmol/l KCl, 1.8mmol/l CaCl2,
1.2mmol/l MgSO4, 1.2mmol/l KH2PO4, 25mmol/l NaHCO3,
0.026mmol/l EDTA, and 11.1mmol/l glucose, pH¼ 7.4)) was
perfused through the renal artery at 3ml/min, and was discarded
through the renal vein. Urine fractions were collected from a
catheter placed in the urinary bladder, starting before the perfusion
with Krebs (when blood was still passing through the kidney), and
for 2 h after perfusion with Krebs started. All urine samples were
kept at 80 1C until assayed by western blot for the presence of
reg IIIb and gelsolin.
Statistical analysis
Data are represented as the mean±s.e. of n experiments performed,
as indicated in each case. Except for the study of proteomic results
(as indicated above), statistical comparisons were assessed by one-
way analysis of variance.
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